8-KMaterial AgreementsFinancial EventsOther Events+1

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Jun 25, 2007)

Filed June 25, 2007For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on June 25, 2007, detailing significant financing activities. The company issued and sold a substantial amount of senior notes, raising approximately $788.3 million in net proceeds after completing the sale on June 22, 2007. This issuance includes $375 million of 6.40% Senior Notes due 2017 and $425 million of 6.95% Senior Notes due 2037. The filing also indicates that these new notes, along with existing borrowings under the company's credit facility, will be guaranteed by the same group of subsidiaries following the execution of several supplemental indentures. These supplemental indentures, dated June 22, 2007, and June 25, 2007, incorporate newly acquired entities, specifically from the HemoCue and AmeriPath acquisitions, as additional subsidiary guarantors. This consolidation of guarantees across financing obligations aims to streamline and strengthen the overall guarantee structure for the company's debt.

Key Highlights

  • 1Quest Diagnostics issued $800 million in aggregate principal amount of Senior Notes (6.40% due 2017 and 6.95% due 2037).
  • 2The company received net proceeds of approximately $788.3 million from the sale of these notes.
  • 3The notes are senior unsecured obligations and rank equally with other senior unsecured debt of the company and its guarantors.
  • 4Several supplemental indentures were executed to add acquired subsidiaries (from HemoCue and AmeriPath acquisitions) as additional guarantors.
  • 5The company's bank credit facility borrowings will also be guaranteed by the same subsidiaries as the new notes.
  • 6The Indenture includes covenants limiting the company's ability to create liens, enter sale and leaseback transactions, merge, or transfer substantially all assets.
  • 7A change of control triggering event requires the company to offer to repurchase the notes at 101% of their principal amount plus accrued interest.

Frequently Asked Questions

The primary purpose of this 8-K filing was to report the entry into a material definitive agreement concerning the issuance and sale of $800 million in aggregate principal amount of Quest Diagnostics' Senior Notes due 2017 and 2037, and to disclose related financing activities and guarantee enhancements due to recent acquisitions.

Quest Diagnostics raised approximately $788.3 million in net proceeds from the sale of the $375 million of 6.40% Senior Notes due 2017 and $425 million of 6.95% Senior Notes due 2037.

The filing indicates that through several supplemental indentures, newly acquired subsidiaries from the HemoCue and AmeriPath acquisitions have been added as guarantors. This ensures that all outstanding notes issued under the Indenture and borrowings under the company's bank credit facility are guaranteed by the same set of subsidiaries, consolidating and strengthening the guarantee structure.

The notes are senior unsecured obligations. The Indenture contains covenants that restrict the company's ability to create certain liens, enter into sale and leaseback transactions, merge or transfer substantially all assets, incur indebtedness of non-guarantor subsidiaries, and make restricted payments. Additionally, a change of control event triggers an offer to repurchase the notes at 101% of their principal amount.